Overview

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Eflornithine
Sulindac